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Recent PTO Guidance Charts a New Course Through the Patent
Eligibility Quagmire
Christopher M. Holman ∗
ABSTRACT
In a span of four years, 2010-2014, the U.S. Supreme Court issued
four decisions that have dramatically altered patent eligibility
jurisprudence: Bilski, Mayo, Myriad, and Alice. Ever since Bilski
was decided, the PTO has struggled to apply the new patent
eligibility jurisprudence in a consistent and predictable manner. The
two part framework for assessing patent eligibility, as set for in Alice
and Mayo, is stated at a high level of abstraction, and the Supreme
Court has given little concrete guidance as to how it is to be applied
beyond the specific claims at issue in its precedent. At times, the
Supreme Court’s explanation of patent eligibility seems internally
inconsistent, for example with respect to method of treatment
claims. Judges on the Federal Circuit have complained that
Supreme Court precedent, particularly the Mayo decision, denies
patent eligibility to some of the most important innovation occurring
in medicine, particularly in the realm of diagnostics and
personalized medicine, which could not have been what the
Supreme Court intended. There have been increasing calls for the
Supreme Court or Congress to intervene and straighten out what
many consider to be a mess, including many of the judges on the
Federal Circuit. The PTO in particular has struggled to implement
the Supreme Court’s recent patent eligibility jurisprudence in a fair,
predictable, and consistent manner. The PTO has responded to the
challenge by issuing a series of guidance documents for use by its
examiners in assessing patent eligibility, along with examples
applying the guidance to specific hypothetical claims, mostly
involving information technology and biotechnology.
This
guidance has been revised with each Supreme Court decision, and
continues to evolve as the Federal Circuit issues precedential
opinions applying the new patent eligibility standard in a variety of
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contexts. This Article reviews the most recent guidance and offers
an assessment of where things stand after the PTO’s latest October
2019 Update with respect to examination for patent eligibility.

In a span of four years, 2010-2014, the U.S. Supreme Court issued four decisions that have
dramatically altered patent eligibility jurisprudence: Bilski, Mayo, Myriad, and Alice. 1 Prior to
Bilski, the perceived scope of patentable subject matter in the U.S., as set forth in decisions of the
Court of Appeals of the Federal Circuit, appeared to encompass nearly any innovation that could
be claimed as a product or process, so long as it provided some “useful, concrete, and tangible
result.” 2 Bilski announced a substantial heightening of the bar, rendering patent eligibility a
substantial hurdle to be overcome by those seeking to patent some innovations that prior to Bilski
had easily satisfied the standard, particularly with respect to business methods and information
technology. The Myriad and Mayo decisions explicitly expanded the heightened stringency into
the realm of biotechnology, rendering patent eligibility a significant, if not insurmountable, bar
to the patenting of important innovations in the life sciences, particularly those involving
diagnostics and natural products.
Alice represented the culmination of this jurisprudential shift, establishing the current framework
for assessing patent eligibility, commonly referred to as the Alice/Mayo test or framework (I will
refer to it as simply the Alice test). This test consists of two steps. Step 1 asks whether the claim
as a whole is “directed to” one of the judicial exceptions to patent eligibility established in earlier
Supreme Court precedent, i.e., an abstract idea, law of nature, or natural phenomena. If the
answer is yes, the inquiry proceeds to Step 2, which asks whether the claimed invention
incorporates enough “more,” beyond the judicial exception, to justify patent eligibility. Step 2 is
often referred to as a search for an “inventive concept,” which generally requires the exclusion of
elements that would not be considered “well-understood, routine, and conventional” at the time
of invention. If the answer to Step 2 is no, i.e., the claim lacks sufficient inventive concept, the
claim recites patent ineligible subject matter, and is unpatentable irrespective of how useful and
nonobvious the subject matter might be.
The Alice test arose out of decisions involving process claims, and is of questionable use in
assessing the patent eligibility of products. Some Federal Circuit decisions have explicitly found
that the Alice test is not the appropriate test for a claim directed towards a natural product, and
that instead Myriad should be applied to natural products. Myriad is the only decision out of the
four to address the patent eligibility of product claims, and it held that a product is only patent
1

Bilski v. Kappos, 561 U.S. 593 (2010), Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012),
Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), Alice Corp. Pty. v. CLS Bank Int'l,
573 U.S. 208 (2014)
2
See, e.g., State Street Bank & Trust Co. v. Signature Financial Group, Inc., 149 F.3d 1368, 1373 (1998) and AT &
T Corp. v. Excel Communications, Inc., 172 F.3d 1352, 1357 (1999).
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eligible if it possesses “markedly different characteristics” than any naturally occurring
counterpart. These characteristics can be structural and/or functional. The U.S. Patent and
Trademark Office (PTO), on the other hand, instructs its examiners to apply the Alice test to both
product and process claims. In the case of product claims, the PTO incorporates Myriad’s
“markedly different characteristics” test into Step 1 of the Alice test.
Ever since Bilski was decided, the PTO has struggled to apply the new patent eligibility
jurisprudence in a consistent and predictable manner. The Alice test is stated at a high level of
abstraction, and the Supreme Court has given little concrete guidance as to how it is to be applied
beyond the specific claims at issue in its precedent. At times, the Supreme Court’s explanation
of patent eligibility seems internally inconsistent, for example with respect to method of
treatment claims. Judges on the Federal Circuit have complained that Supreme Court precedent,
particularly the Mayo decision, denies patent eligibility to some of the most important innovation
occurring in medicine, particularly in the realm of diagnostics and personalized medicine, which
could not have been what the Supreme Court intended. 3 There have been increasing calls for the
Supreme Court or Congress to intervene and straighten out what many consider to be a mess,
including many of the judges on the Federal Circuit. 4
Former chief judge of the Federal Circuit Paul Michel filed an amicus curiae brief with the
Supreme Court on his own behalf urging the Court to grant certiorari in a recent Federal Circuit
decision that found an important medical diagnostic innovation patent ineligible under Mayo,
and to revise its patent eligibility jurisprudence in a manner that allows for the patentability of
diagnostic methods of the type at issue in the case, and other important innovations in
biotechnology. In the words of judge Michel, the “Federal Circuit’s menagerie of patenteligibility decisions over the past decade are devoid of any semblance of consistency [, and] have
created an unbounded and detrimental uncertainty in biotechnology innovation. …[T]he utter
doctrinal confusion has created a legal quagmire that impedes technological progress and the
societal benefits that flow from groundbreaking innovation.” 5
The PTO in particular has struggled to implement the Supreme Court’s recent patent eligibility
jurisprudence. 6 The PTO has no authority to make substantive law, and is required to do its best
to apply the patent law as it has been interpreted by the courts. The PTO employs thousands of
patent examiners, many of whom are non-attorneys, and it is important to provide guidance that
allows these examiners to apply the new test for patent eligibility in a fair, predictable, and
consistent manner. This became an incredibly difficult undertaking in the wake of Bilski and its
progeny.
The PTO has responded to the challenge by issuing a series of guidance documents for use by its
examiners in assessing patent eligibility, along with examples applying the guidance to specific
3

See, e.g., Athena Diagnostics, Inc. v. Mayo Collaborative Servs., 927 F.3d 1333 (Fed. Cir. 2019).
Id.
5
Brief of the Hon. Paul R. Michel (Ret.) as Amicus Curiae in Support of Petitioners, Athena Diagnostics, Inc. v.
Mayo Collaborative Servs., U.S. Supreme Court Docket No. 19-430 (November 1, 2019).
6
84 Fed. Reg. 50 (2019).
4
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hypothetical claims, mostly involving information technology and biotechnology. This guidance
has been revised with each Supreme Court decision, and continues to evolve as the Federal
Circuit issues precedential opinions applying the new patent eligibility standard in a variety of
contexts. After Alice was decided in 2014, for example, the PTO issued its 2014 Interim
Guidance on Patent Subject Matter Eligibility (2014 IEG). 7 This was followed by the July 2015
Update On Subject Matter Eligibility, the May 2016 Subject Matter Eligibility Update, the 2016
Memoranda On Subject Matter Eligibility Decisions, the December 2016 Business Method
Example Update, and the 2018 Memoranda and Notice on Subject Matter Eligibility Decisions. 8
All of the guidance documents issued prior to January 2018 have been incorporated into the
latest edition of the Manual of Patent Examining Procedure (MPEP). 9 The PTO has stated that
any guidance issued prior to January 2018 should not be relied upon.
On January 7, 2019, the USPTO issued its 2019 Revised Patent Subject Matter Eligibility
Guidance (2019 PEG), 10 which refines and clarifies some aspects of the guidance provided in the
MPEP, most particularly with respect to the assessment of whether a claim or claim element is
“directed to” a judicial exception. The public was invited to comment on the 2019 PEG, and in
October the USPTO released its October 2019 Update: Subject Matter Eligibility, 11 which
responds to comments received with further explanation and examples, with the focus on
clarifying practice for patent examiners. This Report offers an assessment of where things stand
after the October 2019 Update with respect to examination for patent eligibility at the PTO.

MPEP § 2106
The MPEP sets forth a two-step process for examiners to assess whether a patent claim qualifies
as eligible subject matter under 35 USC § 101, illustrated by a flow chart. 12 Beginning with Step
1, the examiner is to assess whether the claim is directed towards one of the four categories of
statutory patent eligible subject matter explicitly set forth in Section 101, i.e., a process, machine,
manufacture, or composition of matter. If not, the claim is not patent eligible. If the answer to
Step 1 is yes, the examiner is directed to consider whether the patent eligibility of the claim is
self-evident; if that is the case, the examiner can decide that the claim qualifies as patent eligible
subject matter without engaging in any further analysis. The MPEP refers to this as
“streamlined” analysis. 13 If the analysis cannot be streamlined in this way, the examiner is
directed to proceed to Step 2, which is broken down into two parts. Step 2A asks whether the
claim is “directed to” a judicial exception, i.e., a law of nature, a natural phenomenon (product of
nature), or an abstract idea. If not, the claim is patent eligible. If the claim is found to be
7

79 Fed. Reg. 74618 2014).
PTO website, Subject matter eligibility (examination guidance by date of issuance), available at
https://www.uspto.gov/patent/laws-and-regulations/examination-policy/subject-matter-eligibility-examinationguidance-date
9
Manual of Patent Examining Procedure (MPEP) § 2601, Ninth Edition, Revision 08.2017, (revised January 2018).
10
84 Fed. Reg. 50 (2019).
11
84 Fed. Reg. 55942 (2019).
12
MPEP § 2106(III).
13
Id.
8
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directed to a judicial exception, the examiner is to proceed to Step 2B, which asks whether the
claim recites additional elements that amount to “significantly more” than the judicial exception,
i.e., an inventive concept. If the answer is yes, the claim is patent eligible, if not, the claim is
directed towards subject matter that is not patent eligible.
Step 2A begs the question of what it means for a patent claim to be “directed to” a judicial
exception. This is the language used by the Supreme Court in Mayo and Alice, but the Court has
provided little in the way of guidance as to what it means for a patent claim to be “directed to” a
judicial exception. The MPEP states that a “claim is directed to a judicial exception when a law
of nature, a natural phenomenon, or an abstract idea is recited (i.e., set forth or described) in the
claim.” 14 The MPEP goes on to clarify that a claim can “recite” a judicial exception in one of
two ways, either by “setting forth” the exception, or by “describing” the exception. A claim
“sets forth” an exception when it contains discrete language identifiable as a judicial exception.
Examples include the mathematical equation set forth in the repetitively calculating step in the
claims at issue in Diehr, and the law of nature set forth in the “wherein clause” set forth in the
Mayo claims. 15 The MPEP points to the claims at issue in Alice as an example in which the
patent ineligible concept of intermediated settlement was “described” despite the fact that the
claims do not explicitly use the words “intermediated” or “settlement.” 16
While the language cited above suggests that “directed to” equates with “recites,” elsewhere the
MPEP states that “[s]ome claims reciting an abstract idea are not directed to the act abstract idea
because they also recite additional elements (such as an improvement) demonstrating that the
claims as a whole clearly do not seek to type the abstract idea. In such claims, the improvement,
or other additional elements, shifts the focus of the claimed invention from the abstract idea that
is incidentally recited.” 17 Taken in whole, the MPEP appears to be saying that a claim is
“directed to” a judicial exception if it recites that judicial exception, unless the judicial exception
is only “incidentally recited.” For guidance as to what it means for a judicial exception to be
only “incidentally recited,” the MPEP points to MPEP §§ 2106.05(a) and 2106.06(b) for
examples of the “types of improvements that the courts have identified as indicative of eligibility
in the first stop of the Alice/Mayo test (Step 2A).” 18 These sections of the MPEP provide
examples of Federal Circuit decisions in which the Federal Circuit found that a patent claim
reciting a judicial exception was nonetheless not directed towards that exception because the
claim provided a technological solution to a technological problem, such as improved computer
functionality.

2019 Revised Patent Subject Matter Eligibility Guidance
On January 7, 2019, the USPTO issued its 2019 Revised Patent Subject Matter Eligibility
Guidance (2019 PEG), refining and clarifying its guidance with respect to Step 2A in the
14

MPEP § 2106.04(II)
Id. (citing Diamond v. Diehr, 450 U.S. 175 (1981)).
16
Id.
17
MPEP § 2106.04(a)(1)(II)
18
Id.
15
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eligibility analysis, which asks whether the claim is “directed to” a judicial exception. 19 The
2019 PEG explicitly supersedes MPEP § 2106.04(II), the section of the MPEP that addresses the
PTO’s Step 2A. The 2019 PEG applies to all applications, and to all patents resulting from
applications, filed before, on, or after January 7, 2019, i.e., it is being applied retroactively. 20
The 2019 PEG is intended to provide greater clarity and predictability in the procedure for
examining patent claims for subject matter eligibility, and it does so primarily by revising the
examination procedure with respect to the PTO’s Step 2A, which corresponds to the first step of
the Alice test. 21 In particular, the 2019 PEG introduces two changes into the examination
procedure, by: (1) providing groupings of subject matter that is considered an abstract idea; and
(2) breaking down Step 2A into two distinct Prongs, for the purpose of clarifying that a claim is
not “directed to” a judicial exception if the judicial exception is “integrated” into a practical
application of that exception. 22 In other words, mere recitation of a judicial exception does not
necessarily mean that a claim is “directed to” that judicial exception, it is only “directed to” the
exception under circumstances in which it has not been integrated into a practical application.

Groupings of abstract ideas
The 2019 PEG sets forth groupings of abstract ideas that are intended to enable USPTO
personnel to more readily determine whether a claim recites subject matter that is an abstract
idea. The 2019 PEG notes that prior to this the PTO had provided guidance to the patent
examining corps in the form of specific examples of subject matter that had been identified as an
abstract idea (or not) in Supreme Court and post-Bilski Federal Circuit decisions. The 2019 PEG
notes that while that approach was effective in the immediate aftermath of Alice, it has since
become impractical. The number of Federal Circuit decisions addressing the issue has increased,
and in some cases subject matter has been described as an abstract idea in one judicial decision,
while in another case very similar subject matter has been described as not an abstract idea. In
short, it is becoming increasingly difficult to reconcile the growing body of precedent. With the
expanding and at times inconsistent caselaw, the PTO has found it more and more difficult for
examiners to apply the judicial precedent in a predictable manner, and this raises the concern that
“different examiners within and between technology centers may reach inconsistent results.” 23
The 2019 PEG “extracts and synthesizes key concepts identified by the courts as abstract ideas”
to arrive at the following groupings of subject matter that constitute an abstract idea when recited
as such in a claim limitation(s): (1) mathematical concepts; (2) certain methods of organizing
human activity, such as fundamental economic principles or practices, commercial or legal
interactions, and managing personal behavior relationships or interactions between people; and
(3) mental processes. Only under “rare circumstances” is a claim that does not recite subject
matter falling within one of these enumerated categories to be treated as reciting an abstract idea.
Furthermore, a patent examiner is not permitted to conclude that a claim recites an abstract idea
19

84 Fed. Reg. 50 (2019).
Id.
21
Id.
22
Id.
23
Id.
20
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if it does not recite subject matter falling within one of these categories, unless the examiner
follows a special process applicable to these rare circumstances, which entails approval by the
Technology Center Director and justification for why the claim limitation is being treated as
reciting an abstract idea. 24

Revised Step 2A
The 2019 PEG cites to Supreme Court and Federal Circuit precedent for the proposition that a
patent claim is not “directed to” a judicial exception if that claim integrates the exception into a
practical application, and sets forth a revised Step 2A designed to facilitate the determination of
whether a claim that recites a judicial exception integrates that exception into a practical
application. A claim is not “directed to” a judicial exception, and is thus patent eligible, if the
claim as a whole integrates the recited judicial exception into a practical application of the
exception.
The 2019 PEG subdivides Step 2A into two Prongs. In Prong One, the examiner is instructed to
evaluate whether the claim recites a judicial exception. For abstract ideas, Prong One represents
a change as compared to prior guidance. Previously, examiners were instructed to compare the
claimed concept to the USPTO’s “Eligibility Quick Reference Sheet Identifying Abstract Ideas,”
which provided specific examples of claim limitations that had been found to constitute abstract
ideas. These examples were taken from Supreme Court and Federal Circuit precedent. Under
the 2019 PEG, in contrast, examiners are instructed to (1) identify the specific limitation(s) in the
claim under examination (individually or in combination) that the examiner believes recites an
abstract idea; and (2) determine whether the identified limitation(s) fall within the subject matter
grouping of abstract ideas enumerated in the 2019 PEG, as described above. If the claim is
found not to recite a judicial exception, it is patent eligible, and this concludes the analysis.
However, if the claim recites a limitation (or limitations) falling within one of the enumerated
categories, the examiner is instructed to proceed to Prong Two, as described below. In the rare
circumstance in which an examiner believes a claim limitation that does not fall within the
enumerated groupings nonetheless recites an abstract idea, the claim is to be analyzed according
to the special process described above.
The 2019 PEG states that for the other judicial exceptions, laws of nature and natural
phenomena, Prong One does not represent a change. Examiners are to continue following
existing guidance to identify whether a claim recites one of these exceptions, and if it does,
proceed to Prong Two.
In Prong Two, the examiner is instructed to evaluate whether the claim as a whole integrates the
recited judicial exception into a practical application of the exception. As set forth in the 2019
PEG, a “claim integrates a judicial exception into a practical application when it applies, relies
on, or uses the judicial exception in a manner that imposes a meaningful limit on the judicial
exception, such that the claim is more than a drafting effort designed to monopolize a judicial

24

Id. at 56-57.
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exception.” 25 If the exception is so integrated, then the claim is not directed to a judicial
exception and is patent eligible. If the exception is not so integrated, then the claim is directed to
the judicial exception, and the analysis proceeds to Step 2B and a determination of whether the
claim embodies an inventive concept.
The 2019 PEG instructs examiners to evaluate integration into a practical application by: (1)
identifying whether there are any additional elements recited in the claim beyond the judicial
exception(s); and (2) evaluating those additional elements individually and in combination to
determine whether they integrate the exception into a practical application. The 2019 PEG
provides a number examples of considerations that indicate that an additional element (or
combination of elements) may have integrated the exception into a practical application. These
considerations include any additional element that: (1) reflects an improvement in the
functioning of a computer, or improvement to other technology or technical field; (2) applies a
judicial exception to effect a particular treatment or prophylaxis for a disease or medical
condition; (3) implements a judicial exception with, or uses a judicial exception in conjunction
with, a particular machine or manufacturer that is integral to the claim; (4) affect transformation
or reduction of a particular article to a different state or thing; or (5) applies or uses the judicial
exception and some other meaningful way beyond generally linking the use of the judicial
exception to a particular technological environment. Those familiar with the Federal Circuit’s
decision that was the subject of the appeal in Bilski will recognize that considerations (3) and (4)
explicitly incorporate the Federal Circuit’s “machine or transformation” test, which the Supreme
Court in Bilski held is not the sole and fundamental test for patent eligibility, although it can
serve as useful guidance in assessing patent eligibility. 26
Some of these considerations were discussed in prior PTO guidance in the context of Step 2B
(inventive concept), but the 2019 PEG states that evaluating them in the context of Step 2A
promotes early and efficient resolution of patent eligibility, and improves certainty and
reliability. The 2019 PEG notes that, unlike Step 2B, Prong Two of revised Step 2A specifically
excludes consideration of whether an additional element represents well-understood, routine,
conventional activity. Examiners are instructed to ensure that they give weight to all additional
elements, regardless of whether or not they are conventional, when evaluating whether a judicial
exception has been integrated into a practical application under Prong Two.
The 2019 PEG notes that the list of considerations provided is not exclusive, and there may be
other examples of integrating an exception into a patent application that do not fall into any of
these categories. The guidance also provides examples in which courts have found that a judicial
exception has not been integrated into a practical application, such as when an additional element
in the claim: (1) merely recites the words “apply it” (or an equivalent) with the judicial
exception, or merely includes instructions to implement an abstract idea on a computer, or
merely uses a computer as a tool to perform an abstract idea; (2) adds insignificant extra-solution
25
26

Id. at 53.
Bilski v. Kappos, 561 U.S. 593 (2010).
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activity to the exception; or does no more than generally link the use of a judicial exception to a
particular technological environment or field of use.
If the examiner concludes after conducting the Prong Two analysis that the claim is directed to a
judicial exception, the analysis proceeds to Step 2B, i.e., an evaluation of whether the claim
embodies an inventive concept. Although the 2019 PEG does not revise the analysis under Step
2B, it does specifically point out that there is an overlap between the considerations to be
evaluated under Step 2B and under Prong Two of the revised Step 2A, and that in many cases a
consideration need not be reevaluated in Step 2B if it was already evaluated under Prong Two.
At the same time, examiners are instructed to consider at Step 2B whether an additional element
or combination of elements considered in Prong Two might add a specific limitation or
combination of limitations that are not well-understood, routine, conventional activity in the
field, which is indicative that inventive concept may be present, even if the judicial exception
was not found to be integrated into a practical application at Prong Two.
An additional element or combination of elements that simply appends well-understood, routine,
conventional activities previously known in the industry, specified at a high level generality, to
the judicial exception is indicative that an inventive concept may not be present. On the other
hand, an examiner could find that an additional element constitutes insignificant extra-solution
activity under Prong Two, but that under Step 2B the element is unconventional or otherwise
more than what is well-understood, routine, conventional activity in the field. This finding may
indicate that an inventive concept is present and that the claim is thus eligible.

October 2019 Update
The public was invited to comment on the 2019 PEG, and in October the USPTO released its
October 2019 Update: Subject Matter Eligibility, which responds to comments that were
received with further explanation and examples, with the focus on clarifying practice for patent
examiners. 27 Among other things, the Update provides additional guidance on identifying
abstract ideas using the enumerated groupings provided in the 2019 PEG. For example, it
provides more explanation and examples taken from caselaw with respect to each of the
groupings, i.e., mathematical concepts, certain methods of organizing human activity, and mental
processes. With respect to mental processes, the Update explains that while a claim limitation
that cannot be practically performed in the human mind does not represent a mental process,
because it can only be practically performed through the use of a computer or other machine, a
claim limitation that can be performed practically in human mind does recite a mental process.
Two examples from biotechnology are provided. In University of Utah Research Foundation v.
Ambry Genetics Corp., the Federal Circuit held that claims to “comparing BRCA sequences in
determining the existence of alterations” can practically be performed in the human mind. 28
Similarly, in Classen Immunotherapies, Inc. v. Biogen IDEC, the Federal Circuit held that a
claim limitations of collecting and comparing known information can practically be performed in
27
28

84 Fed. Reg. 55942 (2019).
774 F.3d 755, 763 (Fed. Cir. 2016).
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human mind. 29 The Update further states that even a recited process step that is limited to
performance on a computer can be classified as a mental process if, under the broadest
reasonable interpretation of the claim, the process could be practically performed by the human
mind, perhaps with the aid of a pen and paper.
The Update introduces a “treatment/prophylaxis” consideration, pursuant to which a claim can
integrate a judicial exception into a practical application by applying or using the judicial
exception to effect a particular treatment or prophylaxis for a disease or medical condition.
Much of the genesis of this consideration comes from the Federal Circuit’s Vanda decision. 30
The treatment/prophylaxis consideration applies not only to laws of nature and natural
phenomena, the exceptions most often associated with method of treatment claims, but also to
abstract ideas, such as the mental comparison of immunization-related information, which was
practically applied in Classen Immunotherapies, Inc. v. Biogen IDEC by actually immunizing
mammals in accordance with a particular immunization schedule. 31 The Update identifies the
following factors as relevant in determining whether a claim applies or uses a recited judicial
exception to effect a particular treatment or prophylaxis for a disease or medical condition: (1)
the particularity or generality of the treatment or prophylaxis, (2) whether the limitation(s) have
more than a nominal or insignificant relationship to the exception(s), and (3) whether the
limitation(s) are merely extra-solution activity or a field of use.

New examples
Prior to 2019, the PTO had released 36 examples applying the Alice test to a variety of
hypothetical inventions and claims, mostly involving information technology or biotechnology,
broadly defined. 32 These 36 examples have been retained, but the 2019 PEG introduced six
more examples (Examples 37-42), and an additional four examples were introduced in the
October Update (Examples 43-46). 33 Only two of the examples, Examples 43 and 44, relate to
biotechnology, the others generally relate to information technology and invoke the abstract idea
exception, or in some cases no exception at all. Examples 43 and 44 recite a law of nature and a
product of nature, respectively, and claim 43 further recites an abstract idea.
Example 43 illustrates the application of revised Step 2A to five method of treatment claims
directed towards a personalized medicine invention, wherein a diagnostic test is used to identify
a certain category of patients (non-responders), and tailors the treatment to the patient’s status as
a responder or non-responder. Claim 1, which recites a step of “administering a treatment to the
patient,” without any restrictions on the nature of the treatment, is found to be patent ineligible,
because at Prong Two of Step 2 it is determined that the claim did not integrate a recited judicial
exception into a practical application, because the treatment limitation is stated at such a high
level of generality and does not meaningfully limit the claim. In contrast, hypothetical Claims 229

659 F.3d 1057, 1067 (Fed. Cir. 2011).
Vanda Pharm. Inc. v. W.-Ward Pharm. Int'l Ltd., 887 F.3d 1117 (Fed. Cir. 2018).
31
659 F.3d 1057, 1067 (Fed. Cir. 2011).
32
PTO’s website, Subject matter eligibility, available at https://www.uspto.gov/patent/laws-andregulations/examination-policy/subject-matter-eligibility
33
Id.
30
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4 are deemed patent eligible because they limit the treatment to either “a non-steroidal agent
capable of treating [a specified disease],” rapamycin, or a course of plasmapheresis, respectively.
Because these elements are deemed to constitute a “particular treatment or prophylaxis” under
the 2019 PEG, the claims are found to integrate the exception into a practical application, and
therefore not to be directed towards a judicial exception. Claim 5, which recites a treatment
method comprising “administering rapamycin to a patient identified as having [a particular
disease],” but does not recite a diagnostic test, is found to be patent eligible at Prong One of Step
2A, because a method of treating a disease with the drug does not set forth or describe any
recognized exception.
Example 44 analyzes four exemplary claims relating to a hypothetical natural product (“denveric
acid”) useful in the treatment of diabetes. Claim 1 recites a “dosage unit comprising denveric
acid in a container.” This claim is found to be directed to an exception in the form of a naturebased product limitation (the denveric acid), and at Prong Two of the analysis the claim is found
not to have integrated the judicial exception into a practical application, because the only
additional element is the “container.” Given that denveric acid must be placed in a container in
order to store and use it, the recitation of a container fails to meaningfully limit the claim. At
best, the PTO concludes, it is “the equivalent of merely adding the words ‘apply it’ to the judicial
exception.”
Claim 2, on the other hand, limits the container to a specific delivery device. Although the
background of this example explains that this delivery device is well-understood, and is routinely
used to administer other medications, Prong Two analysis excludes consideration of whether a
limitation as well-understood, routine, conventional activity. The delivery device was evaluated
under the “particular machine” consideration, using the three factors set forth in MPEP
2106.05(b). The delivery device is found: (1) not to be recited at a high level generality, (2) to
constitute an integral part of the claim, and (3) to be more than just a field of use or other
insignificant limitation. Thus, the product of nature exception is integrated into a practical
application, and accordingly Claim 2 is not directed to a judicial exception.
Claim 3 is limited to non-naturally occurring variants of denveric acid that have been chemically
modified so as to be effective for a longer duration than naturally occurring denveric acid, i.e., an
“intermediate-acting” denveric acid. At Prong One of the analysis this claim is found to not
recite the natural product, because the intermediate-acting product has markedly different
functional characteristics than its naturally occurring, “short-acting” counterpart.
Claim 4 recites a dosage unit of denveric acid in combination with protamine. At Prong One of
the analysis, the markedly different characteristics analysis is applied to a nature-based product
produced by combining multiple naturally occurring components (the denveric acid and
protamine), rather than the component parts. Because denveric acid and protamine do not occur
together in nature, there is no naturally occurring counterpart mixture for comparison, and so the
claimed mixture is compared to its naturally occurring components. Denveric acid by itself has
relatively short-acting glycemic control characteristics, and protamine by itself has no glycemic
control characteristics. In combination, they provide intermediate-acting glycemic control,
which is found to constitute a change in functionality, in that the glycemic control characteristics
of the mixture are different than the mere “sum” of the glycemic control characteristics of the
11
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individual components. This distinguishes the example from Funk Brothers, in which the
Supreme Court held a bacterial mixture to be patent ineligible because each species of bacteria in
the mixture continued to have “the same effect as it always had,” i.e., it lacked markedly
different characteristics. 34

Conclusion
The 2019 PEG should significantly improve the patent examination process, not only in terms of
consistency and predictability, but also in more accurately distinguishing between claims that
merely recite a judicial exception versus inventions that apply abstract ideas and natural laws to
solve practical problems. Former chief judge of the Federal Circuit Paul Michel has stated that
the 2019 PEG and October Update represent “impressive progress on providing clearer guidance
to the innovation community,” and that in his view they are a “very important step forward.” 35 I
would hope that the Federal Circuit endorses the essence of the PTO’s revised approach to
assessing whether a patent claim is directed to a judicial exception, as it could help to address the
concern that under the Federal Circuit’s current interpretation of Mayo and Alice too many
meritorious inventions are being denied patent eligibility.
Writing in dissent from the en banc court’s decision to deny rehearing in Athena Diagnostics v.
Mayo, Judge Moore correctly observed that “[n]one of my colleagues defend the conclusion that
claims to diagnostic kits and diagnostic techniques, like those at issue [in this case], should be
ineligible.” 36 Judge Moore, joined by Judges O’Malley, Wallach, and Stoll, argues that a
majority of her colleagues on the Federal Circuit have mistakenly interpreted Mayo tying their
hands in a manner that compels the conclusion that all medical diagnostic inventions are patent
ineligible. She disagrees, and interprets Mayo as allowing the lower courts the discretion to
uphold the patent eligibility of meritorious diagnostic inventions such as the one at issue in
Athena Diagnostics, pointing to substantial differences between the Athena claims and the claims
at issue in Mayo.
Probably most important insight reflected in the 2019 PEG is the emphasis on distinguishing
between a claim or claim element that merely “recites” a judicial exception, versus a claim or
claim element that is “directed to” a judicial exception, as well as the analytical tools for making
the distinction, and in particular the two prong approach to deciding whether a claim is directed
to a judicial exception. In some unfortunate cases, both at the PTO and in the courts, a claim that
recites a judicial exception has been too quickly characterized as being directed to that exception,
with the patent eligibility analysis then proceeding directly to the second step of the Mayo test,
the search for inventive concept. The inventive concept is typically found to be lacking based on
the conventional nature of the additional elements recited in the claim. It is highly significant
that under Prong Two of Step 2A of the PTO’s revised examination process examiners are
specifically instructed to take into account conventional, well-understood, and routine elements
in determining whether a claim integrates a recited exception into a practical application.
34

Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948).
Brief of the Hon. Paul R. Michel (Ret.) as Amicus Curiae in Support of Petitioners, Athena Diagnostics, Inc. v.
Mayo Collaborative Servs., U.S. Supreme Court Docket No. 19-430 (November 1, 2019).
36
Athena Diagnostics, Inc. v. Mayo Collaborative Servs., 927 F.3d 1333 (Fed. Cir. 2019).
35
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To see how this might play out with respect to a diagnostic invention, consider the claims at
issue in Athena Diagnostics. 37 Representative Claim 1 recited a “method for diagnosing
neurotransmission or developmental disorders related to [MuSK] in a mammal comprising the
step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of [MuSK].” 38
The panel majority found that Claim 1, and the claims that depended from it, recited a natural
law, e.g., “the correlation between the presence of naturally-occurring MuSK autoantibodies in
bodily fluid and MuSK-related neurological diseases like MG.” 39 The court went on to conclude
that the claims at issue (which depended from Claim 1) were directed to the natural law because
the “additional recited steps only apply conventional techniques to detect that natural law.” 40
Under the 2019 PEG’s revised examination procedure, in contrast, it would have been improper
not to give due consideration to these additional recited steps at Prong Two solely because they
involve conventional techniques. If the Federal Circuit had taken this approach in Athena
Diagnostics, which I think would be permissible under Mayo and the other relevant Supreme
Court precedent, it might have come to the conclusion that the claims were not directed towards
a natural law, and thus that the claims are patent eligible. All of the judges on the Federal Circuit
seem to agree this would have been the correct outcome, given the overall policy objectives of
patent law and the nature of the claimed invention, and I agree with Judge Moore that
intervention by the Supreme Court and/or Congress is not required to uphold the patent
eligibility of truly meritorious innovations in medical diagnostics and personalized medicine.

37

Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, 915 F.3d 743 (Fed. Cir. 2019).
Id. at 747.
39
Id. at 750.
40
Id. at 751.
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